Tilbake til: Farma og medisin
Innlegg av: aborum (12.09.17 15:54 ), lest 4375 ganger
Ticker: TRVX
Endret: 12.09.17 16:27

TRVX - starter ONCOS-102 studie sponseres af Luwdig

Oslo, Norway, 12 September 2017: Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces start of patient recruitment in phase I/II study to investigate the safety, biologic and anti-tumor activity of trial of ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies.

The sponsor of the study is Ludwig Institute for Cancer Research.

For further information regarding the trial, please visitClinicalTrials.Gov.

For further information, please contact:

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email:renate.birkeli@targovax.com

Media and IR enquires:

Jan Petter Stiff -Crux Advisers
(Norway)

Phone: +47 995 13 891
Email:stiff@crux.no

Julia Phillips/Simon Conway -FTI Consulting
(International)

Phone: +44 20 3727 1000
Email:Targovax@fticonsulting.com
About Targovax

Arming the patients immune system to fight cancer

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

The Companys development pipeline is based on two novel proprietary platforms:

The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines. ONCOS exclusively uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells. In phase I studies it has demonstrated immune activation at lesional level which was associated with clinical benefit. In an ongoing phase I trial in advanced melanoma we expect important proof of concept data for checkpoint inhibitor refractory patients.

The second, TG, is a target specific, neo-antigen therapeutic cancer vaccine platform that solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platforms therapeutic potential stems from its ability to enable a patients immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.

Targovaxs development pipeline has three novel therapeutic candidates in clinical development covering six indications.

Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, Targovax has other products in early stages of development.

In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the shares moved to Oslo Børs, the main Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via Globenewswire